Ignite Creation Date:
2025-12-25 @ 4:16 AM
Ignite Modification Date:
2026-01-28 @ 5:13 PM
Study NCT ID:
NCT06040320
Status:
RECRUITING
Last Update Posted:
2025-10-28
First Post:
2023-09-09
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)
Sponsor:
Washington University School of Medicine
Organization: